Acquisition by Timothy Warbington of 20000 shares of Creative Medical at 0.605 subject to Rule 16b-3
| CELZ Stock | USD 2.32 0.05 2.20% |
Slightly above 53% of Creative Medical's investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Creative Medical Technology suggests that some traders are interested. Creative Medical's investing sentiment can be driven by a variety of factors including economic data, Creative Medical's earnings reports, geopolitical events, and overall market trends.
Creative |
Filed transaction by Creative Medical Technology Director, Officer President Ceo. Grant, award or other acquisition pursuant to Rule 16b-3
Read at macroaxis.com
Creative Medical Fundamental Analysis
We analyze Creative Medical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Creative Medical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Creative Medical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Return On Equity
Return On Equity Comparative Analysis
Creative Medical is currently under evaluation in return on equity category among its peers. Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Creative Medical Tec Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Creative Medical stock to make a market-neutral strategy. Peer analysis of Creative Medical could also be used in its relative valuation, which is a method of valuing Creative Medical by comparing valuation metrics with similar companies.
Peers
Creative Medical Related Equities
| CDIO | Cardio Diagnostics | 15.09 | ||||
| ATXI | Avenue Therapeutics | 5.71 | ||||
| ZVSA | ZyVersa Therapeutics | 4.23 | ||||
| ICU | LMF Acquisition | 2.34 | ||||
| SNGX | Soligenix | 2.13 | ||||
| VRAX | Virax Biolabs | 1.87 | ||||
| UNCY | Unicycive Therapeutics | 1.64 | ||||
| SONN | Sonnet Biotherapeutics | 1.32 | ||||
| REVB | Revelation Biosciences | 2.44 | ||||
| QNRX | Quoin Pharmaceuticals | 3.39 | ||||
| ADXN | Addex Therapeutics | 3.51 | ||||
| PALI | Palisade Bio | 10.84 |
Additional Tools for Creative Stock Analysis
When running Creative Medical's price analysis, check to measure Creative Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Creative Medical is operating at the current time. Most of Creative Medical's value examination focuses on studying past and present price action to predict the probability of Creative Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Creative Medical's price. Additionally, you may evaluate how the addition of Creative Medical to your portfolios can decrease your overall portfolio volatility.